Table 1 Baseline characteristics.

From: Factors associated with adverse drug reactions or death in very elderly hospitalized patients with pulmonary tuberculosis

Variables

All patients

No event

ADR or death within 60 days

p value

(n = 632)

(n = 364)

(n = 268)

Age > 85 years

336 (53.2)

182 (50.0)

154 (57.5)

0.063

Female

251 (39.7)

147 (40.4)

104 (38.8)

0.689

BMI < 18.5 m2/kg

332 (52.5)

180 (49.5)

152 (56.7)

0.071

Polypharmacya

150 (23.7)

87 (23.9)

63 (23.5)

0.908

 Immunosuppressantsb

25 (4.0)

14 (3.8)

11 (4.1)

0.869

ADL, dependent

468 (74.1)

241 (66.2)

227 (84.7)

 < 0.001

Smoking history

267 (42.2)

156 (42.9)

111 (41.4)

0.717

Disease status

 Cavitation on chest X-ray

182 (28.8)

100 (27.5)

82 (30.6)

0.391

 Extrapulmonary TB and/or extensive disease

267 (42.2)

132 (36.3)

135 (50.4)

 < 0.001

 Sputum smear ≥ 2 + 

235 (37.2)

129 (35.4)

106 (39.6)

0.290

Respiratory failure

166 (26.3)

65 (17.9)

101 (37.7)

 < 0.001

Comorbidities

 At least 1 comorbidity

472 (74.7)

256 (70.3)

216 (80.6)

0.003

 Chronic lung diseases

132 (20.9)

68 (18.7)

64 (23.9)

0.112

 Chronic heart diseases

170 (26.9)

91 (25.0)

79 (29.5)

0.210

 Chronic liver diseases

21 (3.3)

12 (3.3)

9 (3.4)

0.966

 Chronic renal diseases

76 (12.0)

45 (12.4)

31 (11.6)

0.761

 Neurological disorders

216 (34.2)

125 (34.3)

91 (34.0)

0.920

 Active malignancy

59 (9.3)

30 (8.2)

29 (10.8)

0.271

 Diabetes mellitus

148 (23.4)

84 (23.1)

64 (23.9)

0.814

 Autoimmune diseases

32 (5.1)

20 (5.5)

12 (4.5)

0.564

 HIV positive

0 (0)

0 (0)

0 (0)

Laboratory findings

 Albumin < 2.5 g/dL

195 (30.9)

77 (21.2)

118 (44.0)

 < 0.001

 Abnormal AST and/or ALTc

160 (25.3)

84 (23.1)

76 (28.4)

0.131

 Renal failure (CCr < 30 mL/min)

202 (32.0)

105 (28.8)

97 (36.2)

0.050

  1. BMI, body mass index; ADL, activities of daily living; TB, tuberculosis; HIV, human immunodeficiency virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CCr, creatinine clearance.
  2. Data are presented as numbers (percentages).
  3. aConcomitant drugs ≥ 7.
  4. bImmunosuppressive drugs within the previous 30 days and/or corticosteroids in daily doses of at least 10 mg/day of a prednisone equivalent for more than two weeks.
  5. cAbove the upper limit of normal range before treatment initiation of TB.